Because a common oncogenic defect in basal-a/TNBC tumor cells is the loss of the retinoblastoma tumor suppressor (Rb1) [46], a cytostatic CDK4/6 drugs that target Rb1 function was investigated as a mechanism to enhance the therapeutic window for Mps1 inhibition. Here, CDK4 is linked to neoplasm.